A new drug, Fruzaqla, has been approved in Brazil to treat patients with metastatic colorectal cancer. This treatment, based on fruquintinib, expands the available options for those who have already undergone chemotherapy. By targeting receptors related to vascular endothelial growth factor, it limits the formation of new blood vessels, thereby slowing tumor progression. This advancement is crucial for patients seeking new therapeutic solutions.